Thor Medical

Mindre end 1K følgere

TRMED

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Oversigt

Investorkonsensus

Thor Medical is a manufacturer and supplier of alpha particle emitters for cancer treatment. Radionuclide therapy (RNT) or radioligand therapy (RLT) using alpha particle emitters is a promising technology for cancer treatment. The main focus of the company is to refine the production technology, secure the customer base and necessary regulatory approvals for industrialization. Thor Medical is headquartered in Oslo.

Markedsværdi

-

Aktieomsætning

-

Omsætning

-

EBIT %

-

P/E

-

Udbytteafkast, %

-

Finanskalender

26.2

2026

Årsrapport '25

23.4

2026

Generalforsamling '26

Alle

Selskabsmeddelelser

ViserAlle indholdstyper

Selskabsmeddelelse4.12.2025, 07.00

TRMED: RadioMedix and Thor Medical enter supply agreement for thorium-228

Pressemeddelelse28.11.2025, 07.39

BioStock: Thor Medical advances toward commercial scale following pilot success and major deal streak

Selskabsmeddelelse20.11.2025, 12.27

Thor Medical ASA - New share capital registered

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Selskabsmeddelelse20.11.2025, 06.30

TRMED: Thor Medical enters supply agreement with NucliThera for thorium-228

Selskabsmeddelelse18.11.2025, 06.30

TRMED: Thor Medical strengthens executive team to realise leadership ambitions in targeted alpha therapies

Selskabsmeddelelse11.11.2025, 22.15

Thor Medical - Issuance of RSU shares to members of the board

Pressemeddelelse7.11.2025, 07.14

BioStock: Thor Medical comments on the Telix agreement

Selskabsmeddelelse6.11.2025, 06.30

TRMED: Thor Medical and Telix Pharmaceuticals sign strategic supply agreement for thorium-228

Selskabsmeddelelse29.8.2025, 05.15

Thor Medical ASA interim results for 1H 2025 - strong operational and commercial progress

Selskabsmeddelelse29.8.2025, 05.00

TRMED: Thor Medical and Oncoinvent Enter Strategic Thorium-228 Supply Agreement

Selskabsmeddelelse22.8.2025, 06.00

Invitation to presentation of Thor Medical ASA's 1H 2025 on Friday 29 August at 08:00

Selskabsmeddelelse4.8.2025, 05.30

TRMED: Thor Medical and AdvanCell expand strategic supply agreement for Thorium-228

Selskabsmeddelelse1.8.2025, 06.58

Thor Medical ASA - Share capital increase in relation to Subsequent Offering is registered

Selskabsmeddelelse4.7.2025, 08.41

Thor Medical ASA: Final results of the Subsequent Offering

Selskabsmeddelelse3.7.2025, 05.00

Thor Medical ASA: The Subscription Period in the Subsequent Offering ends at 16:30 CEST today

Selskabsmeddelelse26.6.2025, 12.33

Thor Medical ASA: Primary insider notification and disclosure of large shareholdings

Selskabsmeddelelse26.6.2025, 12.24

Thor Medical ASA - Share capital increase in relation to the Private Placement and the PrimaryBid Offering is registered

Selskabsmeddelelse26.6.2025, 05.00

Thor Medical ASA: Commencement of the subscription period for the subsequent offering

Selskabsmeddelelse25.6.2025, 16.58

Thor Medical ASA: Registration of national prospectus and launch of subsequent offering

Selskabsmeddelelse19.6.2025, 05.30

Thor Medical ASA: Ex. right to participate in subsequent offering today

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.